# Universal CAR-γδT Cell Injection in the AML Patients

> **NCT05388305** · NA · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- AML

## Interventions

- **BIOLOGICAL:** CAR--γδT cells

## Key facts

- **NCT ID:** NCT05388305
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-20
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388305, "Universal CAR-γδT Cell Injection in the AML Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05388305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*